Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?
- First Online:
- Cite this article as:
- Tchaikovski, V. & Lip, G.Y.H. Curr Hypertens Rep (2012) 14: 183. doi:10.1007/s11906-012-0263-x
The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.